Febrile neutropenia resident survival guide: Difference between revisions
No edit summary |
No edit summary |
||
Line 36: | Line 36: | ||
{{familytree | | | | | | | B01 | | | | | |B01='''Consider the diagnosis of neutropenic fever'''<br><font color="red">POTENTIALLY LIFE THREATENING</font>}} | {{familytree | | | | | | | B01 | | | | | |B01='''Consider the diagnosis of neutropenic fever'''<br><font color="red">POTENTIALLY LIFE THREATENING</font>}} | ||
{{familytree | | | | | | | |!| | | | | | |}} | {{familytree | | | | | | | |!| | | | | | |}} | ||
{{familytree | | | | | | | | {{familytree | | | | | | | C01 | | | | | |C01=<div style="float: left; text-align: left; width: 30em; padding:1em;">'''Obtain a detailed history:'''<br> | ||
❑ New site specific | ❑ New site specific signs and symptoms of infections and inflammation | ||
:❑ Skin and soft-tissues | |||
:❑ Pulmonary | |||
:❑ Central nervous system | |||
:❑ Urinary tract<br> | |||
❑ Exposure to infections<br> | ❑ Exposure to infections<br> | ||
❑ Prior documented infections or pathogen colonization<br> | ❑ Prior documented infections or pathogen colonization<br> |
Revision as of 23:19, 4 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Synonyms and keywords:
Definition
Neutropenic fever is defined as one oral temperature of ≥38.3°C (101°F) or a temperature of ≥38.0°C (100.4°F) for over one hour. Neutropenia is defined as an absolute neutrophil count (ANC) <500 cells/mm3 or an ANC that is expected to become less than 500 cells/mm3 over the next 48 hours. Profound neutropenia is defined as an ANC <100 cells/mm3. Patients with functional neutropenia have a qualitative abnormality of neutrophil functions despite a normal or elevated ANC, as seen in hematological malignancy, and are at increased risk of infections similarly to patients with low ANC.[1]
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Management
Initial Management
Characterize the symptoms: Symptom suggestive of neutropenic fever:
with
| |||||||||||||||||||||||||||||
Consider the diagnosis of neutropenic fever POTENTIALLY LIFE THREATENING | |||||||||||||||||||||||||||||
Obtain a detailed history: ❑ New site specific signs and symptoms of infections and inflammation
❑ Exposure to infections | |||||||||||||||||||||||||||||
Examine the patient: ❑ Site of previous procedures (entry and exit sites of catheters, bone marrow aspiration site) | |||||||||||||||||||||||||||||
Order lab tests and cultures: Labs every 3 days during the course of antibiotics: Labs weekly during the course of antibiotics Cultures: Additional tests (not routine) | |||||||||||||||||||||||||||||
DO A RISK ASSESSMENT | |||||||||||||||||||||||||||||
LOW RISK ❑ MASCC score* ≥21 ❑ Expected brief neutropenia (≤ 7 days) ❑ Clinically stable patient ❑ No comorbidities | HIGH RISK ❑ MASCC score* <21, OR | ||||||||||||||||||||||||||||
Outpatient oral antibiotics (Urgent) ❑ Ability to tolerate oral medications | Inpatient IV antibiotics (Urgent) ❑ Inability to tolerate oral medications | Inpatient IV antibiotics (Urgent) | |||||||||||||||||||||||||||
Administer oral antibiotics: ❑ ciprofloxacin + amoxicillin/clavulanate Observe and discharge: | Administer IV monotherapy with an antipseudomonal: ❑ Cefepime, OR ❑ Piperacillin/tazobactam, OR ❑ Carbapenem | ||||||||||||||||||||||||||||
Modify antibiotics if necessary: Add vancomycin if: Cover for organisms in case of previous infection, colonization, high endemicity: | |||||||||||||||||||||||||||||
Management 2 to 4 Days After Initiation of Antibiotic Treatment
Do's
- Modify the antibiotic regimens depending on the clinical picture and the epidemiology of infections in the area and the hospital where the patient is being treated at.
Don'ts
- Don't measure the temperature of the patient in the axillary area because it is not as specific as if it was taken orally.
- Don't measure the temperature of the patient rectally to avoid contaminating the skin and soft tissues of the rectal area.
References
- ↑ Freifeld, AG.; Bow, EJ.; Sepkowitz, KA.; Boeckh, MJ.; Ito, JI.; Mullen, CA.; Raad, II.; Rolston, KV.; Young, JA. (2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clin Infect Dis. 52 (4): e56–93. doi:10.1093/cid/cir073. PMID 21258094. Unknown parameter
|month=
ignored (help)